GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells

BACKGROUND: Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminished its efficacy. JNK-mediated apoptosis is one of the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer
Autors principals: Karanika, Styliani, Karantanos, Theodoros, Kurosaka, Shinji, Wang, Jianxiang, Hirayama, Takahiro, Yang, Guang, Park, Sanghee, Golstov, Alexei A., Tanimoto, Ryuta, Li, Likun, Thompson, Timothy C.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484888/
https://ncbi.nlm.nih.gov/pubmed/26084402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0395-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars